Intrapartum Monitoring Devices Market Size and Share
Intrapartum Monitoring Devices Market Analysis by Mordor Intelligence
The intrapartum monitoring devices market size reached USD 2.45 billion in 2025 and is forecast to climb to USD 3.39 billion by 2030 at a 6.71% CAGR. Growth momentum reflects the rapid pairing of artificial intelligence with traditional cardiotocography, where deep-learning models have achieved 97.9% accuracy in separating fetal and maternal heart signals. Rising pre-term birth prevalence—up 12% in the United States between 2014 and 2022—and the parallel increase in NICU admissions fuel demand for smarter surveillance during labor. Healthcare providers also favor non-invasive technologies that improve maternal mobility; these external systems captured almost 70% of 2024 revenues and continue to expand as reimbursement frameworks reward patient-comfort metrics. Meanwhile, manufacturers differentiate through portable, AI-ready devices that serve rural facilities and emergency teams, a positioning reinforced by policy mandates requiring fetal monitoring hardware in all labor rooms from January 2026.
Key Report Takeaways
- By product type, electrodes held 65.45% of the intrapartum monitoring devices market share in 2024, while monitors are projected to advance at a 7.12% CAGR through 2030.
- By monitoring method, non-invasive systems accounted for 69.91% of the intrapartum monitoring devices market size in 2024 and are growing at 7.21% CAGR to 2030.
- By portability, fixed units controlled 72.34% revenue in 2024; portable solutions are slated for the quickest expansion at 7.34% CAGR.
- By end-user, hospitals commanded 65.56% share in 2024, while specialty clinics exhibit the strongest CAGR of 7.03% toward 2030.
- By geography, North America led with 42.29% 2024 share, whereas Asia-Pacific is poised for the steepest 7.45% CAGR through 2030.
Global Intrapartum Monitoring Devices Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rapid adoption of non-invasive fetal ECG technology | +1.2% | Global, with early adoption in North America & Europe | Medium term (2-4 years) |
| Rising pre-term births & NICU admissions | +1.8% | Global, particularly acute in North America & Asia-Pacific | Short term (≤ 2 years) |
| Government mandates on intrapartum monitoring standards | +0.9% | North America & Europe, expanding to Asia-Pacific | Long term (≥ 4 years) |
| Growth of high-risk pregnancies in women more than 35 yrs | +1.1% | Global, concentrated in developed economies | Medium term (2-4 years) |
| AI-powered real-time labour analytics embedded in CTG systems | +1.3% | North America & Europe, with rapid Asia-Pacific adoption | Short term (≤ 2 years) |
| Reimbursement uplifts for remote labour wards in Sub-Saharan Africa | +0.4% | Sub-Saharan Africa, with spillover to other LMICs | Long term (≥ 4 years) |
| Source: Mordor Intelligence | |||
Rapid Adoption of Non-Invasive Fetal ECG Technology
Non-invasive fetal electrocardiography offers beat-to-beat heart-rate analysis without belts or scalp electrodes, matching or surpassing Doppler accuracy, particularly in high-BMI patients. Its freedom of movement boosts maternal satisfaction scores, a metric now tied to hospital reimbursement. Pandemic-era remote-monitoring pilots validated home-based ECG patches that transmit continuous data to clinicians, lowering exposure risk while sustaining oversight. Health-system purchasing committees thus rank mobility, comfort, and signal robustness as core criteria, pushing suppliers to embed ECG channels into wireless patch platforms. Start-ups focused on AI interpretation layer additional value by converting continuous waveforms into actionable alerts within seconds.
Rising Pre-Term Births & NICU Admissions
Worldwide, 13.4 million babies were born preterm in 2020, equivalent to 9.9% of live births [1]Ellen Bradley, "Born too soon: global epidemiology of preterm birth and drivers for change," Reproductive Health," reproductive-health-journal.biomedcentral.com. In the United States, NICU admissions rose from 8.7% in 2016 to 9.8% in 2023. Each NICU day costs USD 3,000–5,000, making early intrapartum detection financially attractive to payers [2]CDC, “National Center for Health Statistics Natality Files,” cdc.gov. Advanced monitoring that flags decelerations or uterine tachysystole minutes earlier can reduce emergency cesareans and neurodevelopmental morbidity. The trend is amplified by women delaying childbirth; pregnancies in mothers > 35 years carry higher risks and more often trigger continuous electronic surveillance rather than intermittent auscultation.
Government Mandates on Intrapartum Monitoring Standards
CMS Conditions of Participation will obligate U.S. hospitals to keep fetal dopplers and cardiac monitors within immediate reach of every labor room by January 2026 [3]United States Code of Federal Regulations, “Medicare/Medicaid Conditions of Participation for Hospitals,” cfr.gov. Similar requirements surface across Europe as EU-MDR codifies safety and performance benchmarks. Compliance extends beyond hardware to training and traceability, lifting demand for software updates that log staff proficiency and generate audit artifacts. The FDA’s forthcoming Quality System Regulation alignment with ISO 13485, effective February 2026, elevates documentation depth and lifecycle vigilance. These moves collectively standardize baseline technology adoption and incentivize premium analytics that document preventative interventions.
Growth of High-Risk Pregnancies in Women More Than 35 Years
Machine-learning classifiers using maternal age, BMI, and obstetric history now reach 91% accuracy in predicting high-risk pregnancies. As delayed childbearing expands in OECD economies, first-time mothers over 35 represent the fastest-growing cohort. Clinical guidelines prescribe continuous CTG for this demographic, multiplying monitor utilization hours per labor case. Staffing norms require 1:1 nurse-to-patient ratios in high-risk rooms, prompting health systems to lean on smart central stations that aggregate multibed data and surface deterioration early. Color Doppler ultrasound studies confirm abnormal flow indices in such pregnancies correlate with fetal distress, reinforcing continuous monitoring adoption.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High capital outlay for advanced central surveillance stations | -0.8% | Global, particularly acute in emerging markets | Medium term (2-4 years) |
| Stringent FDA & EU-MDR clinical evidence demands | -0.6% | North America & Europe, with global spillover effects | Long term (≥ 4 years) |
| Cyber-security liabilities of Wi-Fi enabled CTG monitors | -0.4% | Global, with heightened concern in developed markets | Short term (≤ 2 years) |
| Shortage of trained obstetric nurses | -0.7% | Global, most severe in rural and underserved areas | Long term (≥ 4 years) |
| Source: Mordor Intelligence | |||
High Capital Outlay for Advanced Central Surveillance Stations
Hospitals investing in multi-bed fetal telemetry platforms often face seven-figure budgets when integration with EHR, cybersecurity hardening, and staff re-training are included. Prisma Health’s USD 41 million smart-bed deployment across 1,500 units illustrates the scale of capital commitments. Procurement tenders such as BARTS Health NHS Trust’s site-wide vital-signs monitoring call for open APIs and ISO 27001 compliance, adding IT overhead. Under-funded community hospitals postpone upgrades, creating a tiered technology landscape where rural mothers receive palpation or intermittent doppler checks instead of continuous CTG.
Stringent FDA & EU-MDR Clinical Evidence Demands
LucidAI’s fetal monitoring application underwent validation on 65,324 ultrasound images from 2,985 fetuses before clearance, reflecting the evidence bar for algorithmic devices. Post-market surveillance now demands real-world performance logging, and annual software updates trigger new regulatory filings. Small manufacturers bear higher per-unit costs, nudging them toward OEM licensing or partnership exits. Simultaneously, the FDA’s cybersecurity guidance obliges patch cycles and vulnerability disclosures, widening the resource gap between incumbents and entrants.
Segment Analysis
By Product Type: Integrated Monitors Outpace Electrode Mainstays
Electrodes retained 65.45% revenue in 2024, underscoring their indispensable role in signal capture across all modalities. Yet monitors post a faster 7.12% CAGR, reflecting demand for multi-parameter, AI-ready platforms that house fetal, maternal, and uterine channels in one chassis. GE’s Novii wireless patch incorporates ECG and EMG within a belt-free shell that elevates patient comfort while satisfying documentation mandates. Samsung’s USD 92.4 million Sonio purchase highlights the premium on ultrasound-linked analytics that augment CTG workflows. Such integrations deliver holistic intrapartum monitoring devices market value propositions that transcend hardware replacement cycles. Electrode unit sales nonetheless rise steadily because each monitor still needs disposable or reusable transducers, preserving a large consumables revenue stream.
Second-generation monitors bundle cloud connectivity and decision support, shifting purchasing criteria from hardware specifications toward software roadmaps. EDAN’s F3 fetal monitor offers on-board CTG analytics, easing interpretation load for junior staff. Vendors exploring subscription-based algorithm updates can smooth revenue while hospitals gain access to continuously improving classifications without capital refresh. The resulting convergence repositions monitors as software platforms backed by consumable electrodes, ensuring lasting traction within the intrapartum monitoring devices market.
By Monitoring Method: External Platforms Sustain Dual Leadership
Non-invasive systems captured 69.91% of 2024 revenue and are forecast for a 7.21% CAGR, maintaining dual leadership in size and growth. External Doppler ultrasound and tocodynamometers dominate routine obstetric care because they avoid cervical dilation and infection risk. Intrapartum monitoring devices market size gains further as new patches relay signals via Bluetooth, freeing mothers to ambulate or use birthing balls without strap readjustments. Internal scalp electrodes and intrauterine pressure catheters remain the precision gold standard when obesity, malpresentation, or signal noise impede external readings. Recent trials show internal CTG neither raises cesarean incidence nor worsens neonatal outcomes versus external monitoring, potentially broadening clinical indications. However, the need for ruptured membranes limits usage.
Hybrid telemetry arranges dual benefits: high-fidelity signals plus mobility. University of Helsinki findings on simultaneous maternal pulse recording confirm that artifact filtering prevents neonatal encephalopathy, accelerating adoption of multiparameter solutions. External platforms therefore evolve to include maternal ECG channels that auto-subtract cross-talk, reinforcing non-invasive dominance inside the intrapartum monitoring devices market.
By Portability: Wireless Units Reshape Deployment Economics
Fixed consoles supplied 72.34% of 2024 revenues but face decelerating share as portable devices grow 7.34% CAGR. Hospital command centers favor fixed racks feeding central viewers and EHR links. Yet rural outreach, ambulance transfers, and surge capacity after unit closures drive mobile purchasing. Melody International’s iCTG, operable on internal battery and mobile networks, shows how portability serves facilities lacking stable power.
Pandemic protocols that separated infected and non-infected cohorts underscored the benefit of moving monitors rather than patients. Wireless patches like Novii blur category lines, delivering fixed-grade readings while untethering women from the bedside. Procurement teams now weigh network reliability, battery endurance, and cybersecurity when evaluating portable proposals—and their decisions set a new competitive cadence in the intrapartum monitoring devices market.
By End-User: Focused Clinics Capture Agility Dividend
Hospitals still account for 65.56% 2024 spend because they manage high-risk deliveries and hold anesthesia and surgical back-up. Yet specialty clinics register a 7.03% CAGR through 2030 as decentralization and value-based reimbursement reward boutique birthing experiences. Clinics differentiate via lower nurse-to-patient ratios, hydrotherapy amenities, and wireless CTG that allows waterbirth compatibility. Australian satisfaction studies place wireless monitoring at the top of patient preference lists, noting perceived empowerment and lower anxiety.
Home-birth segments and tele-consult platforms broaden the “others” bucket, leveraging FDA-cleared consumer devices such as Masimo Stork for post-discharge surveillance. As these channels mature, they collectively chip away at hospital primacy and diversify procurement patterns within the intrapartum monitoring devices market.
Geography Analysis
North America’s 42.29% stake stems from stringent standards and high per-capita healthcare spending. Forthcoming CMS rules compel universal fetal-monitor access, and NICU admissions edging toward 10% of births intensify monitoring sophistication. Yet 2024 saw multiple rural obstetric unit shutdowns and rising malpractice premiums, pushing health systems to pilot tele-CTG hubs that extend oversight without on-site specialists. Vendor partnerships, such as Philips’ collaboration with Georgia health plans for remote maternal programs, illustrate how the intrapartum monitoring devices market adapts to workforce deficits.
Asia-Pacific claims the speed crown at 7.45% CAGR, lifted by maternal mortality reduction drives and urban hospital construction booms. Governments subsidize digital health pilots that outfit district maternity wards with Bluetooth CTG linked to cloud dashboards in tertiary centers. In Japan and South Korea, AI-interpretation pilots expedite decision making, while emerging economies prioritize basic device deployment alongside midwife training. The Asian Development Bank’s integrated-care grants finance hybrid maternal–NCD telemetry networks, further scaling demand.
Europe sits in a regulatory sweet spot: EU-MDR harmonization simplifies cross-border certifications, and established reimbursement structures cover advanced CTG usage. French hospitals using Masimo SafetyNet for premature newborn early discharge evidence willingness to invest in telemonitoring when cost-benefit aligns. Middle East, Africa, and South America remain nascent but promising. Sub-Saharan Africa’s digital-health lens positions mobile CTG as a leapfrog technology in regions lacking fixed infrastructure.
Competitive Landscape
The intrapartum monitoring devices market exhibits moderate fragmentation. GE Healthcare, Philips, and Medtronic anchor the field with diversified portfolios and sizable installed bases. Their strategy pivots on embedding AI modules that convert continuous traces into risk categories, a move exemplified by GE’s AI Innovation Lab that automatically flags decelerations. Samsung’s USD 92.4 million Sonio purchase exemplifies vertical expansion into software that enriches hardware ecosystems. Mid-tier firms such as Edan leverage cost-competitive monitors bundled with analytical firmware for value-driven buyers.
White-space competitors chase cyber-secure architectures. Several FDA safety communications on patient-monitor vulnerabilities spurred demand for devices with secure-boot, encrypted firmware, and authenticated Wi-Fi stacks. Vendors boasting IEC 81001-5-1-certified software differentiate on trust. Portable specialists, including Melody International, target NGOs and rural health ministries with battery-powered kits priced well below central stations. Meanwhile, AI-only start-ups license classification engines that retrofit legacy CTG files, creating recurring revenue patterns.
Partnerships define 2025 activity: Medtronic allied with Philips to fuse Nellcor pulse oximetry into Philips monitors, expediting integrated fetal–maternal dashboards. GE tied up with Raydiant Oximetry for optical fetal oxygenation sensors, anticipating regulatory acceptance of multi-parametric intrapartum indices. These collaborations illustrate convergence, where data-rich multimodal devices anchor long-term platform control over the intrapartum monitoring devices market.
Intrapartum Monitoring Devices Industry Leaders
-
Cardinal Health
-
GE Healthcare
-
Koninklijke Philips N.V.
-
MindChild Medical
-
The Cooper Companies, Inc.
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- July 2025: Medtronic and Philips agreed to integrate Nellcor pulse oximetry and Microstream capnography into Philips bedside monitors, broadening fetal–maternal parameter coverage.
- May 2025: GE Healthcare partnered with Raydiant Oximetry to co-develop integrated fetal oximetry solutions aimed at improving intrapartum decision making/
- May 2025: Melody International unveiled its battery-independent iCTG and Melody i platform at a digital-transformation trade fair, targeting rural and emergency obstetric settings
- March 2025: FDA issued 510(k) clearance for Huntleigh’s CTG Analysis software, adding automated pattern recognition to its fetal monitors.
Global Intrapartum Monitoring Devices Market Report Scope
As per the scope of the report, intrapartum monitoring refers to continual monitoring during labor. The market summed up by considering the monitors and screening electrodes used for intrapartum care.
| Electrodes | Intra-uterine Pressure Catheters (IUPC) |
| Fetal Scalp Electrodes | |
| Uterine Contraction Transducers | |
| Fetal Heart-Rate Transducers | |
| Monitors |
| Invasive |
| Non-Invasive |
| Fixed |
| Portable |
| Hospitals |
| Specilaty Clinics |
| Others |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
| By Product Type | Electrodes | Intra-uterine Pressure Catheters (IUPC) |
| Fetal Scalp Electrodes | ||
| Uterine Contraction Transducers | ||
| Fetal Heart-Rate Transducers | ||
| Monitors | ||
| By Monitoring Method | Invasive | |
| Non-Invasive | ||
| By Portability | Fixed | |
| Portable | ||
| By End-User | Hospitals | |
| Specilaty Clinics | ||
| Others | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Middle East and Africa | GCC | |
| South Africa | ||
| Rest of Middle East and Africa | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
Key Questions Answered in the Report
How large is the intrapartum monitoring devices market in 2025?
The intrapartum monitoring devices market size stands at USD 2.45 billion in 2025.
What CAGR is forecast for intrapartum monitoring devices to 2030?
Revenue is expected to rise at a 6.71% CAGR through 2030.
Which product category is expanding fastest?
Monitors lead growth with a 7.12% CAGR thanks to integrated AI analytics.
Why are non-invasive monitoring methods preferred?
They capture 69.91% of 2024 revenue because they maximize maternal mobility and comfort while meeting clinical accuracy standards.
Which region will post the highest growth rate?
Asia-Pacific is projected for a 7.45% CAGR as governments scale digital maternal-health infrastructure.
How are AI tools changing fetal monitoring?
Deep-learning engines now auto-interpret CTG traces with up to 97.9% accuracy, reducing clinician workload and enhancing early-warning capabilities.
Page last updated on: